TAP accepts and reviews funding inquiries year round.
- Click here to download the initial inquiry form
Send the completed inquiry form and non-confidential presentation to Dr. Jun Xu, Executive Director - TAP Lead, Therapy Acceleration Program® (email@example.com)
How did TAP benefit Forty Seven?
Listen to what the Chief Medical Officer of Forty Seven, Chris Takimoto, has to say about TAP and the value created for his company.
Recently Forty Seven was acquired by Gilead Sciences for $4.9 Billion.
How did TAP benefit Stemline Therapeutics?
Listen to what the SVP of Corporate & Business Development of Stemline, Peter McDonald, has to say about TAP and the value created for his company.
Elzonris® is the first approved therapy for blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare blood cancer.
Due Diligence Process
Typically takes 3-6 months, but varies based on company responsiveness to LLS requests.